MedTrace Logo

The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)

NCT00092118 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1992

Last updated 2022-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of an approved medication on the symptoms of perennial allergic rhinitis (an inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year), in patients who have a history of perennial allergic rhinitis.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Montelukast

one 10 mg tablet, taken once daily at bed time for 6 weeks

DRUG

Comparator: Placebo

one placebo tablet, taken once daily at bed time for 6 weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2004-05-31
Completion
2004-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00092118 on ClinicalTrials.gov